Back to Report Store Home

Breast Cancer Therapeutics in Major Developed Markets to 2020 – Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs

  • Published: Jun-2014
  • Report Code: GBIHC332MR
  • Report Format: pdf

Description

GBI Research, the leading business intelligence provider, has released its latest research: ‘Breast Cancer Therapeutics in Major Developed Markets to 2020 – Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs ’, which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The breast cancer therapeutics market in the eight major markets – The US, The UK, France, Germany, Spain, Italy, Japan and Canada – was worth $9.2 billion in 2013, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.1% to $13.1 billion by 2020. The US had the largest market in 2013, valued at $5.5 billion, equivalent to a global share of 59%, followed by Japan with $871.5m or 9.4% and Italy with $668.5m or 7.2%. Canada had the lowest market share and value of the leading eight at 2.9% and $268.4m, but is expected to witness rapid growth over the forecast period with a CAGR of 6.7%. This will only be surpassed by Japan, which is expected to witness growth at a CAGR of 6.9%.

Scope

  • The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer in the major developed markets.

  • The report includes:

  • • Disease overview, as well as treatment algorithms and treatment usage patterns

  • • Market size and forecast for the breast cancer market from 2012 to 2019

  • • Major marketed products for breast cancer along with a heat map of product performance

  • • In-depth pipeline analysis for global pipeline in breast cancer along with clinical trial failure rate analysis

  • • Key drivers and restraints that have had and are expected to have a significant impact upon the market

  • • Key licensing and co-development agreements that could have impact on growth trends

Reasons To Buy

  • The report will enhance your decision-making capability by allowing you to:

  • • Align your product portfolio to the markets with high growth potential

  • • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth

  • • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer therapeutics market

  • • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies

  • • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards